Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nursing practice

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Nursing practice. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2012-002862-11 Sponsor Protocol Number: CXA-NP-11-04 Start Date*: 2015-07-27
    Sponsor Name:Cubist Pharmaceuticals GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated...
    Medical condition: Ventilated Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed) HU (Completed) SK (Completed) AT (Completed) GR (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001056-17 Sponsor Protocol Number: 3606 Start Date*: 2020-08-14
    Sponsor Name:Kings's College London [...]
    1. Kings's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia.
    Medical condition: Clinically significant agitation in Alzheimer's Diseases
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001499 Agitation mental LLT
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-002782-37 Sponsor Protocol Number: ENT05 Start Date*: 2005-11-17
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: A Randomised Trial of Inhaled Entonox Plus Local Anaesthesia Versus Intravenous Midazolam Plus Local Anaesthesia To Improve Pain Control During Bone Marrow Biopsy
    Medical condition: This study will involve a group of patients requiring diagnostic bone marrow aspiration and biopsy. The reasons for these will include haematological abnormalities of the blood count , which may be...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003458-26 Sponsor Protocol Number: DEBATE Start Date*: 2019-03-25
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: Evaluating inflammatory and immunological changes of HIV-positive patients switching to DTG dual regimen compared to those switching to a triple drugs regimen (B/F/TAF).
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004713-15 Sponsor Protocol Number: 1235-SR-1005 Start Date*: 2006-02-02
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: A Pilot Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flut...
    Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002711-15 Sponsor Protocol Number: GS-US-292-1823 Start Date*: 2015-11-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegr...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004552-64 Sponsor Protocol Number: 131016 Start Date*: 2017-07-03
    Sponsor Name:Center for Digestive Diseases, Karolinska University Hospital
    Full Title: MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical tr...
    Medical condition: Primary or recurrent inoperable pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000984-81 Sponsor Protocol Number: 04-7-010 Start Date*: 2004-09-09
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER
    Medical condition: Arrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat....
    Disease: Version SOC Term Classification Code Term Level
    61 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-004195-20 Sponsor Protocol Number: 05-7-012 Start Date*: 2005-12-12
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation.
    Medical condition: Arrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat...
    Disease: Version SOC Term Classification Code Term Level
    61 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000879-14 Sponsor Protocol Number: CT/11.01 Start Date*: 2011-06-06
    Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.)
    Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).
    Medical condition: Relapsed and Refractory Small Cell Lung Cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000529-20 Sponsor Protocol Number: FENHYDPAI4012 Start Date*: 2008-05-20
    Sponsor Name:Janssen-Cilag Limited
    Full Title: Comparison of Ionsys® and routine care with morphine IV PCA in the management of early post-operative mobilisation, ability to mobilise and in time to Fitness For Discharge (FFD)
    Medical condition: Evaluation of the mobilisation characteristics, clinical use, safety and Ease of Care (EOC) of a Fentanyl Iontophoretic Transdermal PCA system (Ionsys) and morphine IV PCA for management of acute...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004951-55 Sponsor Protocol Number: E2090-AS086-311 Start Date*: 2017-04-24
    Sponsor Name:Eisai Inc.
    Full Title: A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures
    Medical condition: Epilepsy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2006-002207-13 Sponsor Protocol Number: NRA1280023 Start Date*: 2006-06-29
    Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg
    Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial
    Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003553-26 Sponsor Protocol Number: C-II-009 Start Date*: 2012-03-15
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV
    Full Title: A single arm study in metastatic colorectal cancer patients treated with pharmacokinetically (PK) dose adjusted weekly or biweekly 5-fluorouracil (5-FU) regimes.
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003614-27 Sponsor Protocol Number: GIA-DAP-16-005 Start Date*: 2017-08-16
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart)
    Medical condition: TYPE 2 DIABETES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004418-27 Sponsor Protocol Number: HS02/2014 Start Date*: 2015-05-04
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. f. Endokrinologie und Stoffwechsel
    Full Title: Standardized tight blood glucose management versus usual glycaemic control in patients undergoing allogeneic stem cell transplantation – a pilot trial
    Medical condition: Hyperglycaemic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001516-26 Sponsor Protocol Number: CAIN457FDE05 Start Date*: 2022-10-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, placebo-controlled, parallel group, multicenter, 24-week study investigating the efficacy and safety of secukinumab compared to placebo in adult patients with moderate t...
    Medical condition: Rotator cuff tendinopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004859 10080130 Tendinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005072-40 Sponsor Protocol Number: 1235-SR-202-AF Start Date*: 2007-03-12
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study
    Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066664 Recurrent symptomatic atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) DE (Completed) DK (Completed) SK (Completed) HU (Completed) EE (Completed) BG (Completed) LT (Completed) ES (Completed) CZ (Completed) PT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005625-29 Sponsor Protocol Number: VERI-305-AMIO Start Date*: 2008-03-06
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation
    Medical condition: Treatment of Atrial fibrillation (AF). AF is the most common arrhythmia encountered in clinical practice. It is usually associated with age and general physical condition, rather than with a speci...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) LT (Completed) EE (Completed) DK (Completed) CZ (Completed) FI (Completed) SK (Completed) LV (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017838-44 Sponsor Protocol Number: CJO-201 Start Date*: 2010-04-21
    Sponsor Name:Sequel Pharmaceuticals, Inc.
    Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 19:46:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA